

---

# Contents

---

<b>Preface</b> . . . . .	xxiii
Abhishek KUMAR, Priya BATTa and J.P. ANANTH	
<b>Chapter 1. Artificial Intelligence in Healthcare: Principles, Paradigms and Emerging Trends</b> . . . . .	1
Shilpa C. PATIL and Salim Allauddin CHAVAN	
1.1. Introduction . . . . .	2
1.1.1. History of AI in healthcare . . . . .	2
1.2. Principles of AI in healthcare . . . . .	3
1.2.1. Foundational concepts . . . . .	3
1.2.2. Core AI methodologies . . . . .	3
1.2.3. Ethical and philosophical principles . . . . .	5
1.3. Paradigms of AI in healthcare . . . . .	5
1.3.1. Diagnostic paradigms . . . . .	5
1.3.2. Therapeutic paradigms . . . . .	6
1.3.3. Preventive and predictive paradigms . . . . .	7
1.4. Emerging trends in AI-driven healthcare . . . . .	7
1.4.1. Explainable AI (XAI) and interpretability . . . . .	7
1.4.2. Federated and privacy-preserving learning . . . . .	8
1.4.3. Multimodal and hybrid AI models . . . . .	8
1.4.4. Blockchain and AI synergies . . . . .	9
1.4.5. Generative AI in healthcare . . . . .	9
1.5. Challenges and limitations . . . . .	10
1.5.1. Bearing data quality and interoperability . . . . .	10
1.5.2. Algorithmic bias and fairness . . . . .	10
1.5.3. Regulatory/legal challenges . . . . .	10
1.5.4. Clinical validation and barriers to adoption . . . . .	11
1.5.5. Cost, scalability and infrastructure . . . . .	11

---

1.6. Future directions . . . . .	12
1.7. Conclusion . . . . .	12
1.8. References . . . . .	13
<b>Chapter 2. Machine Learning Models for Diagnostic Decision-Making in Neurology . . . . .</b>	<b>17</b>
Sunil Ramrao YADAV and Kalpana MALPE	
2.1. Introduction . . . . .	17
2.2. Overview of ML in healthcare . . . . .	19
2.3. Supervised learning models in neurological diagnosis . . . . .	20
2.3.1. SVMs . . . . .	20
2.3.2. Decision trees and random forests. . . . .	20
2.3.3. Logistic regression and linear models. . . . .	21
2.3.4. Neural network-based supervised models . . . . .	21
2.4. Unsupervised and semi-supervised approaches . . . . .	21
2.4.1. Unsupervised learning in neurological diagnostics . . . . .	22
2.4.2. Semi-supervised learning in neurology . . . . .	22
2.4.3. Advantages in neurology. . . . .	23
2.4.4. Limitations and challenges. . . . .	23
2.4.5. Emerging trends. . . . .	23
2.5. DL for neuroimaging and signal analysis . . . . .	24
2.5.1. CNNs on neuroimaging . . . . .	24
2.5.2. RNNs and time-varying data. . . . .	24
2.5.3. Transformer architectures in neurology. . . . .	25
2.5.4. Multimodal DL . . . . .	25
2.5.5. Explainability in DL models. . . . .	25
2.6. Multimodal and integrative diagnostic models . . . . .	27
2.6.1. Rationale for multimodal integration . . . . .	27
2.6.2. Fusion strategies in multimodal ML. . . . .	27
2.6.3. Applications in neurology . . . . .	28
2.7. XAI and clinical interpretability . . . . .	28
2.7.1. Importance of explainability in neurology . . . . .	29
2.7.2. Approaches to XAI . . . . .	29
2.7.3. Clinical applications of XAI in neurology . . . . .	29
2.8. Future directions in ML for neurological diagnostics. . . . .	30
2.8.1. Federating and cooperative learning . . . . .	30
2.8.2. Genomic and molecular data. . . . .	30
2.8.3. Self-supervised learning and few-shot learning . . . . .	31
2.9. Conclusion . . . . .	31
2.10. References . . . . .	31

<b>Chapter 3. Deep Learning Approaches to Neuroimaging and Brain Mapping</b> . . . . .	35
G.V. RAMDAS and G.M. VAIDYA	
3.1. Introduction . . . . .	35
3.2. Deep learning fundamentals for neuroimaging . . . . .	37
3.2.1. Convolutional neural networks (CNNs) . . . . .	38
3.2.2. Recurrent neural networks (RNNs) and long short-term memory (LSTM) . . . . .	38
3.2.3. Autoencoders and generative models . . . . .	38
3.2.4. Transformer architectures . . . . .	39
3.2.5. Training strategies and optimization . . . . .	39
3.2.6. Interpretability and explainability . . . . .	39
3.3. Applications in structural neuroimaging (MRI, CT) . . . . .	41
3.3.1. Brain tissue segmentation and morphometric analysis . . . . .	41
3.3.2. Cancer detection and classification . . . . .	41
3.3.3. Lesion detection and abnormality detection . . . . .	41
3.3.4. Diffusion MRI and microstructural analysis . . . . .	42
3.3.5. CT imaging applications . . . . .	42
3.3.6. Multimodal structural integration . . . . .	42
3.4. Applications in functional neuroimaging (fMRI, PET, EEG/MEG) . . . . .	43
3.4.1. Functional MRI (fMRI) . . . . .	43
3.4.2. Positron emission tomography (PET) . . . . .	43
3.4.3. Electroencephalography (EEG) . . . . .	44
3.4.4. Magnetoencephalography (MEG) . . . . .	44
3.4.5. Multimodal functional integration. . . . .	45
3.5. Brain mapping and connectomics with deep learning . . . . .	45
3.5.1. Structural connectomics . . . . .	45
3.5.2. Functional connectomics . . . . .	46
3.5.3. Multiscale brain mapping . . . . .	46
3.5.4. The research has a clinical/translational relevance. . . . .	46
3.6. Clinical applications and translational potential. . . . .	46
3.6.1. Neurodegenerative disorders. . . . .	46
3.6.2. Neuro-oncology. . . . .	47
3.6.3. Cerebrovascular disorders . . . . .	47
3.6.4. Epilepsy and seizure prediction . . . . .	47
3.7. Challenges, limitations and future directions . . . . .	48
3.7.1. Data availability and quality . . . . .	48
3.7.2. Generalizability and reproducibility. . . . .	48
3.7.3. Interpretability and trust . . . . .	48
3.7.4. Computational and resource demands. . . . .	49
3.7.5. Future directions . . . . .	49

3.8. Conclusion . . . . .	50
3.9. References . . . . .	50
<b>Chapter 4. Predictive Analytics for Early Detection of Neurodegenerative Disorders . . . . .</b>	<b>53</b>
Debabrata SAHANA and K. GAVHALE	
4.1. Introduction . . . . .	53
4.2. Predictive analytics framework for neurodegenerative disorders . . . . .	55
4.2.1. Data acquisition . . . . .	55
4.2.2. Data preprocessing and feature engineering . . . . .	56
4.2.3. Model development. . . . .	56
4.2.4. Clinical integration and decision support . . . . .	57
4.2.5. Challenges and future directions. . . . .	58
4.3. Applications of predictive analytics in specific neurodegenerative disorders . . . . .	59
4.3.1. Alzheimer’s disease. . . . .	59
4.3.2. Parkinson’s disease . . . . .	60
4.3.3. Amyotrophic lateral sclerosis . . . . .	60
4.3.4. Huntington’s disease . . . . .	61
4.4. Emerging trends and methodological advances. . . . .	62
4.4.1. Multimodal data fusion. . . . .	62
4.4.2. Longitudinal modeling . . . . .	62
4.4.3. Deep learning and advanced AI techniques. . . . .	62
4.4.4. Explainable artificial intelligence (XAI) . . . . .	63
4.4.5. Federated learning and data privacy. . . . .	63
4.4.6. Real-world digital health integration . . . . .	63
4.5. Challenges, ethical considerations and future directions . . . . .	64
4.5.1. Data-related challenges. . . . .	64
4.5.2. Model-related challenges. . . . .	65
4.5.3. Social and ethical exposures . . . . .	65
4.5.4. Clinical translation and adoption . . . . .	66
4.5.5. Future directions . . . . .	66
4.6. Conclusion . . . . .	67
4.7. References . . . . .	67
<b>Chapter 5. AI-Enhanced Stroke Diagnosis, Prognosis and Rehabilitation Pathways . . . . .</b>	<b>71</b>
Rahul PATIL and Fazil SHEIKH	
5.1. Introduction . . . . .	71
5.2. AI in stroke diagnosis . . . . .	73
5.2.1. Importance of early and accurate diagnosis. . . . .	73
5.2.2. AI applications based on neuroimaging. . . . .	73

5.2.3. Stroke subtype differentiations . . . . .	74
5.2.4. Incorporating multimodal biomarkers. . . . .	74
5.2.5. The use of AI in rapid triage and workflow optimization . . . . .	74
5.2.6. Challenges and limitations . . . . .	75
5.3. AI in stroke prognosis. . . . .	75
5.3.1. The need for accurate prognostic models . . . . .	75
5.3.2. Predicting functional outcomes . . . . .	76
5.3.3. Mortality and recurrence risk prediction . . . . .	76
5.3.4. Treatment planning . . . . .	76
5.3.5. Explainability and clinical trust . . . . .	77
5.3.6. Integration with clinical workflow . . . . .	77
5.4. AI in stroke rehabilitation pathways . . . . .	77
5.4.1. Importance of personalized rehabilitation . . . . .	77
5.4.2. Robotics-assisted rehabilitation . . . . .	78
5.4.3. Wearable sensors and real-time monitoring . . . . .	78
5.4.4. Neurofeedback and brain–computer interfaces. . . . .	78
5.4.5. Virtual reality and game-based rehabilitation . . . . .	79
5.4.6. The use of tele-rehabilitation and remote monitoring . . . . .	79
5.4.7. Integration of multimodal data. . . . .	79
5.5. Integration into clinical workflows. . . . .	79
5.5.1. The need for seamless integration . . . . .	79
5.5.2. Decision support systems in practice . . . . .	80
5.5.3. Interoperability and data standards . . . . .	80
5.5.4. Privacy and regulatory considerations . . . . .	80
5.5.5. Acceptance and explainability of clinicians . . . . .	81
5.6. Future directions. . . . .	81
5.6.1. Understandable and reliable AI . . . . .	81
5.6.2. Equity, bias mitigation and fairness . . . . .	82
5.6.3. Federated and privacy-preserving learning . . . . .	82
5.6.4. Multimodal and continuous prognostication . . . . .	82
5.6.5. Scalable tele-rehabilitation and home-based therapy . . . . .	83
5.6.6. Neurotechnology and advanced brain–computer interfaces. . . . .	83
5.7. Conclusion . . . . .	83
5.8. References . . . . .	84
<b>Chapter 6. Computational Biomarker Discovery for Neurological and Psychiatric Disorders. . . . .</b>	<b>87</b>
Chaitnya GODBOLE and Shamla MANTRI	
6.1. Introduction . . . . .	87
6.1.1. Biomarkers defined. . . . .	88
6.2. Computational approaches for biomarker discovery . . . . .	89
6.2.1. Omics-based biomarker discovery . . . . .	90
6.2.2. Imaging-based biomarkers . . . . .	90

6.2.3. Electrophysiological signals and digital phenotyping . . . . .	91
6.2.4. Multimodal data integration . . . . .	91
6.3. Machine learning and AI in biomarker identification. . . . .	92
6.3.1. Supervised learning approaches . . . . .	92
6.3.2. Unsupervised learning approaches . . . . .	92
6.3.3. Deep learning in biomarker discovery . . . . .	93
6.3.4. Multimodal data fusion and integration . . . . .	93
6.3.5. Explainable AI for biomarker discovery . . . . .	95
6.3.6. Transfer learning and federated learning . . . . .	95
6.4. Biomarkers in neurological disorders . . . . .	96
6.4.1. Alzheimer’s disease. . . . .	96
6.4.2. Parkinson’s disease . . . . .	97
6.4.3. Epilepsy . . . . .	97
6.5. Biomarkers in psychiatric disorders . . . . .	98
6.5.1. Major depressive disorder . . . . .	98
6.5.2. Schizophrenia . . . . .	99
6.5.3. Bipolar disorder . . . . .	99
6.5.4. Anxiety disorders . . . . .	100
6.6. Challenges and future directions . . . . .	100
6.6.1. Data heterogeneity and quality. . . . .	100
6.6.2. Sample size and data scarcity . . . . .	101
6.6.3. Interpretability and clinical adoption . . . . .	101
6.6.4. Ethical, legal and privacy concerns . . . . .	101
6.6.5. Future directions . . . . .	102
6.7. Conclusion . . . . .	102
6.8. References . . . . .	103
<b>Chapter 7. Natural Language Processing for Clinical Narratives and Neurological Case Records . . . . .</b>	<b>107</b>
Shrikrishna N. BAMNE and Swapna KAMBLE	
7.1. Introduction . . . . .	108
7.2. NLP fundamentals in clinical narratives. . . . .	109
7.3. Applications in neurology and case records . . . . .	111
7.3.1. Stroke documentation and prognosis . . . . .	111
7.3.2. Dementia and cognitive disorders . . . . .	111
7.3.3. Epilepsy case records . . . . .	112
7.3.4. Parkinson’s disease and movement disorders . . . . .	112
7.3.5. Uncommon and uncharacteristic neurological disorders . . . . .	112
7.4. Advances in model architectures . . . . .	113
7.4.1. Transformer models in clinical NLP . . . . .	114
7.4.2. Large language models (LLMs) . . . . .	114
7.4.3. Neurological multimodal NLP. . . . .	114
7.4.4. Explainability and trustworthiness . . . . .	115

7.5. Clinical Utility: diagnosis, prognosis and treatment support . . . . .	115
7.5.1. Diagnostic support . . . . .	115
7.5.2. Prognostic modeling . . . . .	116
7.5.3. Monitoring and response evaluation of the treatment . . . . .	116
7.5.4. Clinical decision support systems (CDSS) . . . . .	116
7.5.5. Patient engagement and communication . . . . .	117
7.6. Integration with EHR and clinical workflows . . . . .	117
7.6.1. Embedding NLP in EHR systems . . . . .	117
7.6.2. Workflow optimization . . . . .	118
7.6.3. Interoperability and multidisciplinary care . . . . .	118
7.6.4. Barriers to adoption . . . . .	118
7.7. Challenges: bias, privacy, data scarcity and interpretability . . . . .	118
7.7.1. Bottlenecks in data scarcity/annotation . . . . .	119
7.7.2. Privacy and data security . . . . .	119
7.7.3. Bias and fairness . . . . .	119
7.7.4. Interpretability and trust . . . . .	120
7.7.5. Barriers to the organization and implementation . . . . .	120
7.8. Future perspectives . . . . .	120
7.8.1. Multimodal multilingual integration . . . . .	120
7.8.2. Advanced model adaptation and continual learning . . . . .	120
7.8.3. Ethical and responsible AI . . . . .	121
7.8.4. Collaborative research and open science . . . . .	121
7.9. Conclusion . . . . .	121
7.10. References . . . . .	122
<b>Chapter 8. AI-Integrated Wearable Technologies for Continuous Neurological Monitoring . . . . .</b>	<b>125</b>
Swati JAGTAP and Ashish N. PATIL	
8.1. Introduction . . . . .	125
8.2. AI in wearable neurological monitoring . . . . .	127
8.2.1. Wearable sensor modalities . . . . .	127
8.2.2. AI in data processing . . . . .	128
8.2.3. Real-time monitoring and edge AI . . . . .	128
8.3. Clinical applications . . . . .	129
8.3.1. Epilepsy . . . . .	129
8.3.2. Parkinson's disease . . . . .	130
8.3.3. Alzheimer's disease and dementia . . . . .	130
8.3.4. Multiple sclerosis . . . . .	131
8.3.5. Stroke and rehabilitation . . . . .	131
8.3.6. Traumatic brain injury . . . . .	132
8.4. System architecture and data integration . . . . .	133
8.4.1. Data acquisition and preprocessing . . . . .	133
8.4.2. Feature extraction and AI pipelines . . . . .	134

8.4.3. Multimodal sensor fusion . . . . .	134
8.4.4. Edge–cloud collaboration . . . . .	135
8.4.5. Digital twins in neurology . . . . .	135
8.4.6. Security, privacy and interoperability . . . . .	135
8.5. Challenges and limitations . . . . .	136
8.5.1. Data privacy and security . . . . .	136
8.5.2. Algorithmic bias and generalizability . . . . .	136
8.5.3. Interpretability and clinical trust . . . . .	137
8.5.4. Energy efficiency and wearability . . . . .	137
8.5.5. Regulatory and ethical considerations . . . . .	137
8.5.6. Integration with clinical practice . . . . .	138
8.6. Future directions . . . . .	138
8.6.1. Personalized and adaptive neurology . . . . .	138
8.6.2. Explainable and trustworthy AI . . . . .	139
8.6.3. Integration with brain–computer interfaces . . . . .	139
8.7. Conclusion . . . . .	139
8.8. References . . . . .	140
<b>Chapter 9. Epilepsy Forecasting and Seizure Prediction Through AI Algorithms . . . . .</b>	<b>143</b>
Ashwini R. GARGATE and Komal M. JUJAR	
9.1. Introduction . . . . .	144
9.2. Pathophysiology and challenges of seizure prediction . . . . .	145
9.2.1. Pre-ictal traffic jam and variability . . . . .	145
9.2.2. Difficulties with the biomarker identification . . . . .	145
9.2.3. Patient-specific variability . . . . .	146
9.2.4. Ethical and regulatory issues . . . . .	146
9.3. AI in epilepsy forecasting: an overview . . . . .	146
9.3.1. From statistical models to AI-driven forecasting . . . . .	146
9.3.2. AI algorithms that are used . . . . .	147
9.3.3. The main benefits of AI-based solutions . . . . .	147
9.3.4. Restrictions and continued hindrances . . . . .	148
9.4. Machine learning approaches for seizure prediction . . . . .	148
9.4.1. Unifying machine learning via feature engineering . . . . .	148
9.4.2. Classical algorithms of machine learning . . . . .	148
9.4.3. Patient-specific versus generalized models . . . . .	149
9.4.4. Handling imbalanced data . . . . .	149
9.5. Deep learning and neural network models . . . . .	150
9.5.1. Advantages of deep learning over traditional ML . . . . .	150
9.5.2. Convolutional neural networks (CNNs) . . . . .	150
9.5.3. Recurrent neural networks (RNNs) and LSTM models . . . . .	150
9.5.4. Autoencoders and generative models . . . . .	151

9.6. Multimodal data integration for seizure forecasting . . . . .	152
9.6.1. Multimodal data integration . . . . .	152
9.6.2. EEG as the primary modality . . . . .	152
9.6.3. Neuroimaging modalities. . . . .	153
9.6.4. Integration strategies . . . . .	153
9.6.5. Benefits and challenges. . . . .	153
9.7. Wearable devices and real-time forecasting . . . . .	154
9.7.1. Wearable EEG systems. . . . .	154
9.7.2. Physiological wearables other than EEG . . . . .	154
9.7.3. Edge computing and real . . . . .	155
9.7.4. Problems and future perspectives . . . . .	155
9.8. Privacy, ethics and data challenges. . . . .	155
9.8.1. Data privacy concerns . . . . .	155
9.8.2. Ethical considerations . . . . .	156
9.8.3. Regulatory and legal problems. . . . .	156
9.9. Future directions in AI-driven seizure forecasting . . . . .	156
9.9.1. Categorized and adaptation model. . . . .	156
9.9.2. Multimodal systems and sensory modality . . . . .	157
9.9.3. Explainable and clinically trustworthy AI . . . . .	157
9.10. Conclusion . . . . .	157
9.11. References . . . . .	158
<b>Chapter 10. Intelligent Robotic Systems for Neurorehabilitation and Assistive Care . . . . .</b>	<b>161</b>
Debabrata SAHANA and Atul Namdev PAWAR	
10.1. Introduction. . . . .	162
10.2. Principles of intelligent robotic systems . . . . .	162
10.2.1. Human–robot interaction (HRI) . . . . .	162
10.2.2. Task-specific and repetitive training . . . . .	163
10.2.3. Adaptive control and personalization . . . . .	163
10.2.4. Safety and compliance . . . . .	163
10.2.5. Multimodal integration . . . . .	163
10.3. Robotics in neurorehabilitation . . . . .	164
10.3.1. Upper-limb rehabilitation . . . . .	164
10.3.2. Lower-limb rehabilitation and gait training . . . . .	164
10.3.3. Cognitive rehabilitation . . . . .	165
10.4. Assistive robotics for daily living. . . . .	166
10.4.1. Mobility assistance . . . . .	166
10.4.2. Communication and social interaction. . . . .	166
10.4.3. Home-care integration . . . . .	167
10.5. Technological paradigms and enablers . . . . .	167
10.5.1. ML and AI . . . . .	167
10.5.2. Brain–computer interfaces (BCIs) . . . . .	167

10.5.3. Wearable sensors . . . . .	168
10.5.4. IoT and cloud-based integration . . . . .	168
10.6. Clinical evidence and applications . . . . .	168
10.6.1. Evidence in upper-limb rehabilitation . . . . .	168
10.6.2. Evidence in lower-limb and gait training . . . . .	169
10.6.3. Evidence in cognitive and social rehabilitation . . . . .	169
10.6.4. Evidence in home-based and long-term use . . . . .	170
10.7. Challenges and limitations. . . . .	171
10.7.1. Cost, affordability and reimbursement. . . . .	172
10.7.2. Quality of the evidence and long-term outcomes. . . . .	172
10.7.3. Safety, robustness and human factors . . . . .	172
10.7.4. Interoperability and standardization . . . . .	172
10.7.5. Adapting to patient diversity . . . . .	173
10.8. Emerging trends and future directions . . . . .	173
10.8.1. Soft robotics and biomimetic design. . . . .	173
10.8.2. Hybrid neuroprosthetic systems . . . . .	173
10.8.3. Personalized and adaptive therapies . . . . .	174
10.8.4. Tele-robotics and remote care . . . . .	174
10.9. Conclusion . . . . .	174
10.10. References . . . . .	175

**Chapter 11. Personalized Medicine in Multiple Sclerosis Through AI-Driven Analytics . . . . . 179**

Chaitnya GODBOLE and Shrikant Rangrao KADAM

11.1. Introduction. . . . .	180
11.2. Overview of multiple sclerosis and the need for personalization. . . . .	181
11.3. AI in MS diagnosis and early detection . . . . .	181
11.4. AI-driven prognostic modeling in MS . . . . .	183
11.4.1. Relapse prediction. . . . .	183
11.4.2. Disability progression . . . . .	183
11.4.3. Treatment response forecasting . . . . .	183
11.4.4. Longitudinal disease modeling . . . . .	184
11.5. Personalized treatment strategies through AI analytics . . . . .	184
11.5.1. Therapy selection . . . . .	184
11.5.2. Switching and optimization of treatment . . . . .	184
11.5.3. Safety and risk management . . . . .	185
11.5.4. Accurate dose and adherence assistance. . . . .	185
11.5.5. Patient-centered treatment personalization . . . . .	185
11.6. Integration of multi-omics and biomarkers . . . . .	186
11.6.1. Genomics and genetic risk profiling . . . . .	186
11.6.2. Proteomics and biomarker discovery . . . . .	186
11.6.3. Metabolomics and immune profiling . . . . .	186
11.6.4. Multi-omics fusion and forecasting . . . . .	187

11.7. Role of neuroimaging and computer vision . . . . .	187
11.7.1. Automated lesion detection . . . . .	187
11.7.2. Brain and spinal cord atrophy at measurement . . . . .	187
11.7.3. Radiomic predictive modeling and feature extraction . . . . .	187
11.7.4. Completion with multimodal data . . . . .	188
11.8. AI-powered monitoring and patient engagement . . . . .	188
11.8.1. Wearable devices and remote monitoring . . . . .	188
11.8.2. Mobile health platforms . . . . .	188
11.8.3. Real-time predictive analytics . . . . .	188
11.8.4. Patient-centered engagement . . . . .	189
11.9. Challenges, ethical concerns and limitations . . . . .	190
11.9.1. Information quality and workability . . . . .	190
11.9.2. Testing, interpretation and usability . . . . .	190
11.9.3. Ethical and privacy concerns . . . . .	191
11.9.4. Implementation clinically and into workflow . . . . .	191
11.9.5. Limitations of current AI models . . . . .	191
11.10. Future directions and clinical translation . . . . .	191
11.10.1. integration of real-world data . . . . .	191
11.10.2. Multisensory modeling and multidimensional modeling . . . . .	192
11.10.3. AI-assisted clinical trials . . . . .	192
11.10.4. Personalized digital therapeutics and telemedicine . . . . .	192
11.10.5. Ethical and regulatory considerations for future integration . . . . .	193
11.11. Conclusion . . . . .	193
11.12. References . . . . .	193
<b>Chapter 12. Artificial Intelligence Applications in Sleep Medicine and Neurological Disorders . . . . .</b>	<b>197</b>
Swati JAGTAP and Sharifnawaj Y. INAMDAR	
12.1. Introduction . . . . .	198
12.2. AI in sleep medicine . . . . .	199
12.2.1. Sleep stage classification . . . . .	199
12.2.2. Sleep disorder diagnosis . . . . .	200
12.2.3. Wearables and home-based monitoring . . . . .	200
12.3. AI in neurological disorders . . . . .	201
12.3.1. Epilepsy . . . . .	201
12.3.2. AD and dementia . . . . .	201
12.3.3. PD . . . . .	202
12.3.4. MS and other neurological arguments . . . . .	202
12.4. Multimodal data integration and predictive analytics . . . . .	203
12.4.1. Rationale for multimodal approaches . . . . .	203
12.4.2. Integration of neuroimaging, physiological and behavioral data . . . . .	203

12.4.3. Disease progression predictive models . . . . .	204
12.4.4. Predictive modeling for disease progression . . . . .	204
12.4.5. Future perspectives . . . . .	204
12.5. Ethical, legal and clinical challenges . . . . .	206
12.5.1. Data quality, bias and generalizability . . . . .	206
12.5.2. Explainability and clinician trust . . . . .	206
12.5.3. Privacy, data governance and federated learning . . . . .	206
12.5.4. Regulatory and liability considerations . . . . .	207
12.5.5. Equity of access and health system integration . . . . .	207
12.6. Future directions . . . . .	207
12.6.1. Federated, multicenter and open data initiatives . . . . .	207
12.6.2. Hybrid human–AI workflows . . . . .	208
12.6.3. Multimodal foundation models and transfer learning . . . . .	208
12.6.4. Continuous learning with safe update mechanisms . . . . .	208
12.7. Conclusion . . . . .	208
12.8. References . . . . .	209
<b>Chapter 13. Virtual and Augmented Reality Coupled with AI for Cognitive Rehabilitation . . . . .</b>	<b>213</b>
Omkar KULKARNI and Amruta B. KALE	
13.1. Introduction . . . . .	214
13.2. Foundations of cognitive rehabilitation . . . . .	215
13.3. VR in cognitive rehabilitation . . . . .	216
13.4. AR in cognitive rehabilitation . . . . .	217
13.5. AI for adaptive therapy . . . . .	218
13.6. Synergistic role of VR/AR coupled with AI . . . . .	219
13.7. Clinical applications and case studies . . . . .	221
13.7.1. Stroke rehabilitation . . . . .	221
13.7.2. TBI . . . . .	221
13.7.3. Dementia and Alzheimer’s disease . . . . .	221
13.8. Technological innovations and tools . . . . .	222
13.8.1. VR and AR hardware . . . . .	222
13.8.2. Software platforms . . . . .	222
13.8.3. AI implementation and analytics software and applications . . . . .	223
13.9. Challenges and ethical considerations . . . . .	223
13.9.1. Technical challenges . . . . .	223
13.9.2. Ethical and privacy concerns . . . . .	224
13.10. Future directions and research opportunities . . . . .	224
13.11. Conclusion . . . . .	225
13.12. References . . . . .	226

---

<b>Chapter 14. AI-Driven Drug Discovery Pipelines for Neurological and Mental Health Therapies</b> . . . . .	229
Sharad KSHIRSAGAR and Ashish N. PATIL	
14.1. Introduction . . . . .	229
14.2. Principles of AI in drug discovery . . . . .	231
14.2.1. Predictive modeling via ML . . . . .	231
14.2.2. DL and neural networks. . . . .	231
14.2.3. NLP as a knowledge extraction . . . . .	232
14.3. AI in target identification and biomarker discovery. . . . .	232
14.3.1. Multi-omics integration to discover novel targets . . . . .	232
14.3.2. Biomarkers of neuroimaging and AI. . . . .	233
14.3.3. EHR and phenotypic data. . . . .	233
14.4. AI in hit discovery and lead optimization . . . . .	233
14.4.1. Virtual screening and high-throughput prediction . . . . .	234
14.4.2. Generative AI in de novo molecule design . . . . .	234
14.4.3. Optimizing a lead using multi-parameter modeling . . . . .	235
14.5. AI in drug repurposing for neurological and mental health disorders . . . . .	235
14.5.1. Data-driven repurposing strategies. . . . .	235
14.5.2. Literature mining NLP . . . . .	236
14.5.3. Actual data and EHRs. . . . .	236
14.6. AI in preclinical and clinical trial design for neurological and mental health therapies . . . . .	236
14.6.1. AI in preclinical research . . . . .	237
14.6.2. Patient stratification in clinical trials. . . . .	237
14.6.3. Endpoints and biomarkers optimization. . . . .	237
14.6.4. Predictive modeling of good trial results . . . . .	238
14.7. Ethical, regulatory, and societal implications of AI in neurological and psychiatric drug discovery . . . . .	238
14.7.1. Ethical considerations. . . . .	238
14.7.2. Regulatory challenges. . . . .	240
14.7.3. Societal implications . . . . .	240
14.7.4. Pathways forward . . . . .	240
14.8. Future directions and emerging trends in AI-driven drug discovery for neurological and mental health therapies . . . . .	241
14.8.1. Integration of multi-modal data . . . . .	241
14.8.2. Generative AI and automated molecular design . . . . .	241
14.8.3. Digital biomarkers and remote monitoring . . . . .	241
14.8.4. Personalized and adaptive therapeutics . . . . .	242
14.9. Conclusion . . . . .	242
14.10. References. . . . .	242

---

<b>Chapter 15. Ethical, Legal and Societal Implications of AI in Neurology and Medicine</b> . . . . .	245
Dipali JANKAR and Anil SAHU	
15.1. Introduction . . . . .	246
15.2. AI in neurology and medicine: an overview . . . . .	247
15.2.1. AI in diagnostics . . . . .	247
15.2.2. AI in the treatment and prognosis . . . . .	248
15.2.3. AI in research and drug discovery . . . . .	248
15.2.4. Integration into clinical practice . . . . .	249
15.2.5. Opportunities and risks . . . . .	249
15.3. Ethical implications . . . . .	249
15.3.1. Patient autonomy and informed consent . . . . .	249
15.3.2. Data privacy and confidentiality . . . . .	250
15.3.3. Algorithmic bias and fairness . . . . .	250
15.3.4. Transparency and explainability . . . . .	251
15.3.5. Accountability in ethical use . . . . .	251
15.4. Legal implications . . . . .	251
15.4.1. Liability and accountability for errors . . . . .	252
15.4.2. IP rights . . . . .	252
15.4.3. Regulatory frameworks for AI in healthcare . . . . .	252
15.4.4. Compliance with medical and data standards . . . . .	253
15.5. Societal implications . . . . .	253
15.5.1. Fairness and fairness to access AI-enhanced care . . . . .	253
15.5.2. Workforce transformation in medicine . . . . .	254
15.5.3. Patient–physician relationship in the AI era . . . . .	254
15.6. Challenges and future perspectives . . . . .	256
15.6.1. Technical challenges . . . . .	256
15.6.2. Harmonization of ethics and legal alignment . . . . .	257
15.6.3. Social preparedness and inequality in the world . . . . .	257
15.6.4. Pathways for responsible AI deployment . . . . .	257
15.7. Conclusion . . . . .	258
15.8. References . . . . .	258
<b>Chapter 16. Federated Learning and Collaborative AI Models in Neuroscience Research</b> . . . . .	261
Dipali JANKAR and Sanjay L. BADIATE	
16.1. Introduction . . . . .	261
16.2. Fundamentals of FL in neuroscience . . . . .	263
16.2.1. Principles of FL . . . . .	263
16.2.2. FL architectures in applications . . . . .	263
16.2.3. Privacy-preserving mechanisms . . . . .	264
16.2.4. Challenges in implementing FL in neuroscience . . . . .	264

16.3. Collaborative AI models in neuroscience . . . . .	265
16.3.1. Conceptual foundations of collaborative AI. . . . .	265
16.3.2. Multi-institutional AI collaborations. . . . .	265
16.3.3. Human–AI collaboration in neuroscience research. . . . .	266
16.3.4. Multi-modal collaborative AI in neuroscience . . . . .	266
16.4. Applications of FL and collaborative AI in neuroscience. . . . .	267
16.4.1. Neuroimaging applications . . . . .	267
16.4.2. Neural signal analysis and electrophysiology. . . . .	267
16.4.3. Digital biomarkers and remote monitoring . . . . .	268
16.4.4. Cognitive and behavioral neuroscience . . . . .	269
16.4.5. Neurodegenerative and psychiatric disorders . . . . .	269
16.4.6. BCIs and neurotechnology . . . . .	270
16.5. Challenges and limitations of FL and collaborative AI in neuroscience . . . . .	271
16.5.1. Technical challenges . . . . .	271
16.5.2. Regulatory and ethical impediments. . . . .	272
16.5.3. Challenges in the infrastructures . . . . .	272
16.5.4. Cultural and collaborative barriers . . . . .	273
16.5.5. Striking a balance between innovation and responsibility . . . . .	273
16.6. Future directions . . . . .	274
16.7. Conclusion . . . . .	274
16.8. References . . . . .	275
<b>Chapter 17. AI-enabled Approaches for Pain Prediction, Assessment and Management. . . . .</b>	<b>279</b>
Mario ANTONY and Salim Allauddin CHAVAN	
17.1. Introduction. . . . .	279
17.2. AI for pain prediction . . . . .	281
17.2.1. Foundations of AI-based prediction . . . . .	281
17.2.2. Postoperative pain prediction. . . . .	281
17.2.3. Chronic pain forecasting . . . . .	282
17.2.4. Nociceptive and neuropathic pain . . . . .	282
17.2.5. Multimodal data integration . . . . .	282
17.2.6. Barriers to implementation . . . . .	283
17.3. AI for pain assessment. . . . .	283
17.3.1. Deficiencies of traditional pain assessment . . . . .	283
17.3.2. Measuring using physiological signals . . . . .	283
17.3.3. Face recognition . . . . .	284
17.3.4. Voice and speech analysis . . . . .	284
17.3.5. Neuroimaging-based evaluation . . . . .	284
17.3.6. Multimodal fusion approaches . . . . .	284
17.4. AI in pain management . . . . .	285
17.4.1. Personalized analgesic dosing . . . . .	285

17.4.2. Prediction of risk and leadership in opioid stewardship . . . . .	285
17.4.3. Non-pharmacological interventions for pain . . . . .	286
17.4.4. Digital therapeutics and remote monitoring. . . . .	286
17.4.5. Integrative decision-support systems . . . . .	286
17.4.6. RL and adaptive learning models . . . . .	287
17.4.7. AI-based pain management dilemmas . . . . .	287
17.5. Challenges and limitations of AI in pain medicine . . . . .	287
17.5.1. Data scarcity and data quality concerns . . . . .	289
17.5.2. Applicability to some populations . . . . .	289
17.5.3. Embedding in clinical workflow . . . . .	289
17.5.4. Interpretability and trust . . . . .	289
17.5.5. Cost and resource constraints. . . . .	290
17.6. Ethical, legal and future directions . . . . .	290
17.6.1. Data privacy and security. . . . .	290
17.6.2. Unbiased and fair work environments . . . . .	290
17.6.3. Legal liability and accountability . . . . .	290
17.6.4. Patient autonomy and consent . . . . .	291
17.6.5. Future directions. . . . .	291
17.7. Conclusion . . . . .	291
17.8. References . . . . .	292
<b>Chapter 18. Conversational AI and Virtual Assistants for Neurological Patient Support . . . . .</b>	<b>295</b>
Nikhilchandra MAHAJAN and Piyush Ashokrao DALKE	
18.1. Introduction. . . . .	295
18.2. Technological foundations of conversational AI in healthcare. . . . .	296
18.2.1. NLP and understanding . . . . .	296
18.2.2. Discussion management and individualization . . . . .	297
18.2.3. Multimedia interfaces and accessibility . . . . .	297
18.2.4. Data integration and healthcare ecosystems. . . . .	298
18.3. Clinical applications of conversational AI in neurological care . . . . .	298
18.3.1. Medication adherence and symptom tracking. . . . .	298
18.3.2. Cognitive rehabilitation and training. . . . .	299
18.3.3. Emotional support and companionship . . . . .	299
18.3.4. Improvement of communication with speech-impaired patients . . . . .	300
18.3.5. Remote monitoring and telehealth integration . . . . .	300
18.4. Benefits and opportunities of conversational AI for neurological support . . . . .	302
18.4.1. Improving patient engagement and empowerment . . . . .	302
18.4.2. Accessibility and scalability . . . . .	302
18.4.3. Customized and modifiable interventions. . . . .	303
18.4.4. Minimization of social isolation and emotional support . . . . .	303
18.4.5. Interoperability with other broader digital health ecosystems . . . . .	303

18.5. Challenges and limitations. . . . .	304
18.5.1. Accuracy and reliability of interactions . . . . .	304
18.5.2. Data privacy and security issues . . . . .	304
18.5.3. Ethical and social implications . . . . .	304
18.5.4. Barriers to usability and accessibility . . . . .	305
18.5.5. Integration and clinical validation problems . . . . .	305
18.6. Future directions and research opportunities. . . . .	305
18.6.1. Multisensory interfaces and multimodal interfaces. . . . .	306
18.6.2. Integrates BCIs . . . . .	306
18.6.3. Preventive and predictive healthcare paradigms . . . . .	306
18.6.4. Federated learning and privacy-preserving AI . . . . .	307
18.6.5. Emotional intelligence, affective computing . . . . .	307
18.6.6. Broadening clinical evidence and policy frameworks . . . . .	307
18.7. Conclusion . . . . .	308
18.8. References . . . . .	308
<b>Chapter 19. Brain–Computer Interfaces Enhanced by Artificial Intelligence . . . . .</b>	<b>311</b>
Rahul S.S. and Mrudula NIMBARTE	
19.1. Introduction. . . . .	311
19.2. Neural signal acquisition and preprocessing . . . . .	313
19.2.1. Neural signal acquisition modalities . . . . .	313
19.2.2. Challenges in raw signal quality . . . . .	314
19.2.3. Feature extraction and dimensionality reduction . . . . .	314
19.2.4. Adaptive preprocessing and personalization . . . . .	315
19.3. AI-driven neural decoding and feature extraction. . . . .	315
19.3.1. Classical versus AI-based decoding approaches . . . . .	315
19.3.2. Feature extraction using DL . . . . .	316
19.3.3. Transfer learning and domain adaptation . . . . .	316
19.3.4. Attention-based GNNs and mechanisms . . . . .	316
19.3.5. Adaptive and online learning. . . . .	318
19.3.6. On the way to real-time neural decoding . . . . .	318
19.4. Applications of AI-enhanced BCIs . . . . .	318
19.4.1. Medical and neurorehabilitation applications. . . . .	318
19.4.2. Assistive technologies and neuroprosthetics . . . . .	320
19.4.3. Human–computer interaction and entertainment . . . . .	320
19.4.4. Defense and security applications . . . . .	321
19.4.5. Education and workplace applications. . . . .	321
19.5. Challenges, ethical considerations and future directions . . . . .	322
19.5.1. Technical challenges . . . . .	322
19.5.2. Ethical and societal considerations. . . . .	323
19.5.3. Regulatory and legal challenges . . . . .	323
19.5.4. Future directions. . . . .	324

---

19.6. Conclusion . . . . .	324
19.7. References . . . . .	325
<b>Chapter 20. The Future of AI in Neurology: Innovations, Challenges and Strategic Directions . . . . .</b>	<b>329</b>
Sunil Ramrao YADAV and Mrudula NIMBARTE	
20.1. Introduction . . . . .	329
20.2. AI in neurological diagnostics. . . . .	331
20.2.1. AI in neuroimaging . . . . .	331
20.2.2. Electrophysiological diagnostics through AI . . . . .	332
20.2.3. Cognitive and behavioral diagnostics AI . . . . .	332
20.2.4. AI in uncommon and complex neurological diseases . . . . .	332
20.2.5. Multimodal and integrated diagnostics . . . . .	333
20.2.6. Clinical translation and current limitations . . . . .	333
20.3. AI in prognosis and disease progression modeling . . . . .	333
20.3.1. Predicting cognitive decline in Alzheimer’s disease . . . . .	333
20.3.2. Progression modeling in PD . . . . .	334
20.3.3. Stroke recovery prediction . . . . .	334
20.3.4. MS prognosis . . . . .	335
20.3.5. Prognostic models and their applications to clinical practice . . . . .	335
20.4. AI in therapeutics and rehabilitation . . . . .	335
20.4.1. AI in pharmacological and therapeutic development. . . . .	335
20.4.2. Neurorehabilitation with AI . . . . .	336
20.4.3. Therapeutic AI implementation issues. . . . .	337
20.4.4. The new paradigm of individualized neurotherapeutics . . . . .	337
20.5. Challenges and ethical considerations . . . . .	339
20.5.1. Technical challenges . . . . .	339
20.5.2. Ethical challenges . . . . .	340
20.6. Strategic directions for the future . . . . .	341
20.6.1. Clinical translation and regulatory frameworks. . . . .	341
20.6.2. Integration into healthcare systems . . . . .	341
20.6.3. Research priorities. . . . .	341
20.6.4. Global equity and access . . . . .	342
20.7. Conclusion . . . . .	342
20.8. References . . . . .	343
<b>List of Authors . . . . .</b>	<b>347</b>
<b>Index . . . . .</b>	<b>351</b>